查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1594526

非类固醇消炎剂市场：依疾病、药物、给药途径、通路分类 - 全球预测 2025-2030

Non-steroidal Anti-inflammatory Drugs Market by Disease Indication (Arthritis, Migraine, Ophthalmic Diseases), Drugs (Over-the-counter Drugs, Prescription), Route of Administration, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年非类固醇消炎剂市值为217.1亿美元，预计2024年将达232.4亿美元，复合年增长率为7.53%，预计到2030年将达361亿美元。

非类固醇非类固醇消炎剂 非类固醇消炎剂 ）是一类透过抑制Cyclooxygenase来缓解疼痛、减轻发炎、退烧的药物。这些药物对于治疗关节炎、肌肉疼痛和头痛等症状至关重要。非类固醇抗发炎药的范围从缓解轻度至中度疼痛的非处方药到治疗慢性发炎疾病的处方药。最终用途主要包括医疗机构、零售药局和个人使用者。影响非类固醇抗发炎药物市场的主要成长要素包括慢性疼痛疾病盛行率的增加、人口老化以及对疼痛管理选择的认识不断提高。此外，最大限度地减少消化器官系统道副作用并提高非类固醇抗发炎药物有效性的配方的进步也带来了值得注意的市场机会。非类固醇消炎剂配方和联合治疗等创新是业务成长和扩张的潜在途径。

主要市场统计
基准年[2023] 217.1亿美元
预测年份 [2024] 232.4亿美元
预测年份 [2030] 361亿美元
复合年增长率（%） 7.53%

然而，非类固醇抗发炎药物具有消化道出血和心血管风险等副作用，这限制了其使用并增加了监管审查，限制了市场成长。此外，替代疗法（例如治疗发炎疾病的生物製药）的出现对非类固醇抗发炎药物构成了竞争。希望利用 NSAID 市场机会的公司可能会受益于专注于开拓更安全的製剂，例如具有改善的胃肠道安全性的製剂或选择性 COX-2 抑制剂。扩大个人化医疗方法的研究，根据个人的基因特征客製化非类固醇消炎剂（NSAID）治疗，也可以提供竞争优势。非类固醇消炎剂市场竞争激烈，大型製药企业在产品差异化和市场渗透策略上投入大量资金。持续监控监管途径和患者依从模式对于维持成长动能至关重要。参与产品创新的策略伙伴关係和协作研究是有益的。总之，虽然非类固醇消炎剂（NSAID）仍然是疼痛和发炎管理的基石，但解决安全问题和探索新的给药系统将抓住市场潜力，这是最重要的。

市场动态：揭示快速发展的非类固醇消炎剂市场的关键市场洞察

非类固醇消炎剂市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 慢性疼痛病例增加，发炎病例迅速增加
    • 老年人口不断增加，人们对使用非类固醇消炎剂的认识不断提高
    • 更多人喜欢非类固醇抗发炎药而不是鸦片类药物
  • 市场限制因素
    • 与使用非类固醇消炎剂相关的副作用
  • 市场机会
    • 更快的政府核准和更多的政府措施
    • 新技术、研发活动和新药上市
  • 市场挑战
    • 药物在临床试验中失败

波特五力：驾驭非类固醇消炎剂市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解非类固醇消炎剂市场的外部影响

外部宏观环境因素在塑造非类固醇消炎剂市场的表现动态中发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解非类固醇消炎剂市场竞争格局

对非类固醇消炎剂市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵非类固醇消炎剂市场供应商的绩效评估

FPNV定位矩阵是评估非类固醇消炎剂市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，非类固醇消炎剂市场的成功指明道路

对非类固醇消炎剂市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5.产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 慢性疼痛病例增加，发炎病例迅速增加
      • 老年人口不断增加，人们对使用非类固醇消炎剂的认识不断提高
      • 越来越多的人喜欢非类固醇抗发炎药而不是鸦片类药物
    • 抑制因素
      • 与使用非类固醇消炎剂相关的副作用
    • 机会
      • 政府快速核准和政府主导措施增多
      • 新兴技术、研发活动及新药上市
    • 任务
      • 药物在临床试验中失败
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章非类固醇消炎剂市场：依疾病适应症

  • 关节炎
  • 偏头痛
  • 眼科疾病

第七章非类固醇消炎剂市场（依药品）

  • 非处方药
    • 阿斯匹灵（Bufferin、拜耳、Excedrin）
    • Ibuprofen（Advil、Motrin、Nuprin）
    • 酮洛芬（Actron，Ordis）
    • 萘普生（Aleve）
  • 处方笺
    • 日亲
    • 印度支那
    • 罗丹
    • 萘普生
    • 利拉芬
    • 维莫沃
    • Voltaren

第八章非类固醇消炎剂市场：依给药途径

  • 口服
  • 胃肠外的

第九章非类固醇消炎剂市场：依分销管道划分

  • 药局
  • 医院药房
  • 网路药房
  • 零售药房

第十章美洲非类固醇消炎剂市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太非类固醇消炎剂市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章 欧洲、中东和非洲非类固醇消炎剂市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Apotex Inc.
  • Assertio Therapeutics, Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Iroko Pharmaceuticals Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Perrigo Company PLC
  • Pfizer Inc.
  • Reckitt Benckiser Group PLC
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-7C50F2739687

The Non-steroidal Anti-inflammatory Drugs Market was valued at USD 21.71 billion in 2023, expected to reach USD 23.24 billion in 2024, and is projected to grow at a CAGR of 7.53%, to USD 36.10 billion by 2030.

Non-steroidal Anti-inflammatory Drugs (NSAIDs) are a class of medications used to alleviate pain, decrease inflammation, and reduce fever by inhibiting cyclooxygenase enzymes. These drugs are essential in managing conditions like arthritis, muscular pain, and headaches. The application scope of NSAIDs spans over-the-counter use for mild to moderate pain relief and prescription use for chronic inflammatory diseases. The end-use scope primarily includes healthcare facilities, retail pharmacies, and individual users. Key growth factors influencing the NSAID market include increasing prevalence of chronic pain conditions, an aging population, and heightened awareness of pain management options. Moreover, advancements in drug formulations that minimize gastrointestinal side effects and elevate the efficacy of NSAIDs present noteworthy market opportunities. Innovations like topical NSAID forms and combination therapies serve as potential avenues for business growth and expansion.

KEY MARKET STATISTICS
Base Year [2023] USD 21.71 billion
Estimated Year [2024] USD 23.24 billion
Forecast Year [2030] USD 36.10 billion
CAGR (%) 7.53%

However, market growth faces limitations, notably due to the side effects of NSAIDs, such as gastrointestinal bleeding and cardiovascular risks, which can deter usage and lead to stringent regulatory scrutiny. Additionally, the advent of alternative therapies like biologics for inflammatory conditions poses competition to NSAIDs. For companies aiming to capitalize on NSAID market opportunities, focusing on developing safer formulations, such as those with improved gastrointestinal safety profiles or selective COX-2 inhibitors, can be advantageous. Expanding research into personalized medicine approaches that tailor NSAID therapies to individual genetic profiles can also offer a competitive edge. The nature of the NSAID market is highly competitive, with major pharmaceutical companies investing heavily in product differentiation and market penetration strategies. Continued surveillance of regulatory pathways and patient compliance patterns is crucial for maintaining growth momentum. Engaging in strategic partnerships and collaborations for product innovation can be instrumental. In conclusion, while NSAIDs remain a cornerstone in pain and inflammation management, addressing safety concerns and exploring novel drug-delivery systems will be paramount in harnessing market potential.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Non-steroidal Anti-inflammatory Drugs Market

The Non-steroidal Anti-inflammatory Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rise in chronic pain cases and surge in inflammation cases
    • Increasing geriatric population and rising awareness about the use of non-steroidal anti-inflammatory drugs
    • Increasing preference of people for nsaids over opioids
  • Market Restraints
    • Side effects associated with the use of non-steroidal anti-inflammatory drugs
  • Market Opportunities
    • Quick authority approvals by the governments and increase in government initiatives
    • Emerging technology, research and development activities, and launch of novel drugs
  • Market Challenges
    • Failure of drug during the clinical trial

Porter's Five Forces: A Strategic Tool for Navigating the Non-steroidal Anti-inflammatory Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Non-steroidal Anti-inflammatory Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Non-steroidal Anti-inflammatory Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Non-steroidal Anti-inflammatory Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Non-steroidal Anti-inflammatory Drugs Market

A detailed market share analysis in the Non-steroidal Anti-inflammatory Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Non-steroidal Anti-inflammatory Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Non-steroidal Anti-inflammatory Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Non-steroidal Anti-inflammatory Drugs Market

A strategic analysis of the Non-steroidal Anti-inflammatory Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Non-steroidal Anti-inflammatory Drugs Market, highlighting leading vendors and their innovative profiles. These include Apotex Inc., Assertio Therapeutics, Inc., AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Eli Lilly and Company, GlaxoSmithKline PLC, Iroko Pharmaceuticals Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Perrigo Company PLC, Pfizer Inc., Reckitt Benckiser Group PLC, Sanofi S.A., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Non-steroidal Anti-inflammatory Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Disease Indication, market is studied across Arthritis, Migraine, and Ophthalmic Diseases.
  • Based on Drugs, market is studied across Over-the-counter Drugs and Prescription. The Over-the-counter Drugs is further studied across Aspirin (Bufferin, Bayer, & Excedrin), Ibuprofen (Advil, Motrin, Nuprin), Ketoprofen (Actron, Orudis), and Naproxen (Aleve). The Prescription is further studied across Daypro, Indocin, Lodine, Naprosyn, Relafen, Vimovo, and Voltaren.
  • Based on Route of Administration, market is studied across Oral and Parenteral.
  • Based on Distribution Channel, market is studied across Drug Store, Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rise in chronic pain cases and surge in inflammation cases
      • 5.1.1.2. Increasing geriatric population and rising awareness about the use of non-steroidal anti-inflammatory drugs
      • 5.1.1.3. Increasing preference of people for nsaids over opioids
    • 5.1.2. Restraints
      • 5.1.2.1. Side effects associated with the use of non-steroidal anti-inflammatory drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Quick authority approvals by the governments and increase in government initiatives
      • 5.1.3.2. Emerging technology, research and development activities, and launch of novel drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Failure of drug during the clinical trial
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Non-steroidal Anti-inflammatory Drugs Market, by Disease Indication

  • 6.1. Introduction
  • 6.2. Arthritis
  • 6.3. Migraine
  • 6.4. Ophthalmic Diseases

7. Non-steroidal Anti-inflammatory Drugs Market, by Drugs

  • 7.1. Introduction
  • 7.2. Over-the-counter Drugs
    • 7.2.1. Aspirin (Bufferin, Bayer, & Excedrin)
    • 7.2.2. Ibuprofen (Advil, Motrin, Nuprin)
    • 7.2.3. Ketoprofen (Actron, Orudis)
    • 7.2.4. Naproxen (Aleve)
  • 7.3. Prescription
    • 7.3.1. Daypro
    • 7.3.2. Indocin
    • 7.3.3. Lodine
    • 7.3.4. Naprosyn
    • 7.3.5. Relafen
    • 7.3.6. Vimovo
    • 7.3.7. Voltaren

8. Non-steroidal Anti-inflammatory Drugs Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Oral
  • 8.3. Parenteral

9. Non-steroidal Anti-inflammatory Drugs Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Drug Store
  • 9.3. Hospital Pharmacy
  • 9.4. Online Pharmacy
  • 9.5. Retail Pharmacy

10. Americas Non-steroidal Anti-inflammatory Drugs Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Non-steroidal Anti-inflammatory Drugs Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Non-steroidal Anti-inflammatory Drugs Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Apotex Inc.
  • 2. Assertio Therapeutics, Inc.
  • 3. AstraZeneca PLC
  • 4. Bayer AG
  • 5. Boehringer Ingelheim International GmbH
  • 6. Eli Lilly and Company
  • 7. GlaxoSmithKline PLC
  • 8. Iroko Pharmaceuticals Inc.
  • 9. Johnson & Johnson Services, Inc.
  • 10. Merck & Co., Inc.
  • 11. Perrigo Company PLC
  • 12. Pfizer Inc.
  • 13. Reckitt Benckiser Group PLC
  • 14. Sanofi S.A.
  • 15. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY MIGRAINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OPHTHALMIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ASPIRIN (BUFFERIN, BAYER, & EXCEDRIN), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY IBUPROFEN (ADVIL, MOTRIN, NUPRIN), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY KETOPROFEN (ACTRON, ORUDIS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY NAPROXEN (ALEVE), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DAYPRO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY INDOCIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY LODINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY NAPROSYN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RELAFEN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY VIMOVO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY VOLTAREN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUG STORE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 64. MEXICO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. MEXICO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 69. UNITED STATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. UNITED STATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. UNITED STATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 80. AUSTRALIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 82. AUSTRALIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 84. AUSTRALIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. AUSTRALIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. CHINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. CHINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 88. CHINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 89. CHINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 90. CHINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. CHINA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. INDIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. INDIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 94. INDIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 95. INDIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 96. INDIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. INDIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. INDONESIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. INDONESIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 100. INDONESIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 101. INDONESIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 102. INDONESIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. INDONESIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. JAPAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. JAPAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 106. JAPAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 107. JAPAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 108. JAPAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. JAPAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. MALAYSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. MALAYSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 112. MALAYSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 113. MALAYSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 114. MALAYSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. MALAYSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. PHILIPPINES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 118. PHILIPPINES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 120. PHILIPPINES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. PHILIPPINES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. SINGAPORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. SINGAPORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 124. SINGAPORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 125. SINGAPORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 126. SINGAPORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. SINGAPORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH KOREA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH KOREA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH KOREA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. SOUTH KOREA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. TAIWAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. TAIWAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 136. TAIWAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 137. TAIWAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 138. TAIWAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. TAIWAN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. THAILAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. THAILAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 142. THAILAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 143. THAILAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 144. THAILAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. THAILAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. VIETNAM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. VIETNAM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 148. VIETNAM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 149. VIETNAM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 150. VIETNAM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. VIETNAM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 159. DENMARK NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 160. DENMARK NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 161. DENMARK NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 162. DENMARK NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 163. DENMARK NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. DENMARK NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 165. EGYPT NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 166. EGYPT NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 167. EGYPT NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 168. EGYPT NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 169. EGYPT NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 170. EGYPT NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 171. FINLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 172. FINLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 173. FINLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 174. FINLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 175. FINLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 176. FINLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 177. FRANCE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 178. FRANCE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 179. FRANCE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 180. FRANCE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 181. FRANCE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 182. FRANCE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 183. GERMANY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 184. GERMANY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 185. GERMANY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 186. GERMANY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 187. GERMANY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. GERMANY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 189. ISRAEL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 190. ISRAEL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 191. ISRAEL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 192. ISRAEL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 193. ISRAEL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 194. ISRAEL NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 195. ITALY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 196. ITALY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 197. ITALY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 198. ITALY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 199. ITALY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 200. ITALY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 202. NETHERLANDS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 204. NETHERLANDS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 206. NETHERLANDS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 207. NIGERIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 208. NIGERIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 209. NIGERIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 210. NIGERIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 211. NIGERIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 212. NIGERIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 213. NORWAY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 214. NORWAY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 215. NORWAY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 216. NORWAY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 217. NORWAY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 218. NORWAY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 219. POLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 220. POLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 221. POLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 222. POLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 223. POLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 224. POLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 225. QATAR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 226. QATAR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 227. QATAR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 228. QATAR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 229. QATAR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 230. QATAR NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 231. RUSSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 232. RUSSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 233. RUSSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 234. RUSSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 235. RUSSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 236. RUSSIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 238. SAUDI ARABIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 240. SAUDI ARABIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 242. SAUDI ARABIA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 248. SOUTH AFRICA NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 249. SPAIN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 250. SPAIN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 251. SPAIN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 252. SPAIN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 253. SPAIN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 254. SPAIN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 255. SWEDEN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 256. SWEDEN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 257. SWEDEN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 258. SWEDEN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 259. SWEDEN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 260. SWEDEN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 262. SWITZERLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 264. SWITZERLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 265. SWITZERLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 266. SWITZERLAND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 267. TURKEY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 268. TURKEY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 269. TURKEY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 270. TURKEY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 271. TURKEY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 272. TURKEY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY PRESCRIPTION, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED ARAB EMIRATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED ARAB EMIRATES NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED KINGDOM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, 2018-2030 (USD MILLION)
  • TABLE 282. UNITED KINGDOM NON-STEROIDAL ANTI-INFLAMMATORY DRU